From:	Vice Chancellor James S. Economou
To:	dnd@bruinpost.ucla.edu
Subject:	Change in IRB Fees for Industry-Sponsored Clinical Trials
Date:	Tuesday, July 03, 2012 3:32:20 PM

Office of the Vice Chancellor for Research

Deans, Directors, Department Chairs, and Administrative Officers:

A change in the structure and rate of the IRB fees charged for industry-sponsored clinical trials will be phased in beginning immediately as new clinical trial agreements are negotiated. The new rate and structure is being implemented after careful consideration, including analysis of fees charged by other universities and UC campuses, and discussion with the IRB Chairs and research administration staff.

The new fee of $2,500 will be charged for the review of new industry-sponsored clinical trials that meet the following conditions:

- Designed to assess in humans the safety, efficacy, benefits, adverse reactions, and/or other outcomes of drugs, devices, diagnostics, treatments, procedures, medical evaluations, monitoring or preventive measures; and
- Fully supported by an industry sponsor; and
- Meet University contractual requirements for industry-supported clinical trials.

IRB review fees are not charged for clinical studies supported by the National Institutes of Health (NIH) or other government agencies, investigator-initiated studies, or industry-sponsored studies that do not meet the UCLA definition of a clinical trial outlined above.

The IRB review fee is being updated for the first time since 2002. While the fee for review of new studies has been increased to $2,500, the fee for continuing review of studies has been eliminated. The new fee will be charged once per study. All annual renewal fees will be discontinued as of July 1, 2012.

The IRB fee is to be budgeted as a separate line item in the contract budget and reimbursed by the sponsor at the time of contract execution. The invoicing and collection of the fee will be managed by the Office of Research Administration with assistance from the School of Medicine Clinical Trial Administration Office. The fees collected will be deposited into an account used for support of the Office of the Human Research Protection Program (OHRPP) and represent important additional resources needed to support the OHRPP.

If you have questions about the collection of the IRB fee, please contact Marcia Smith in the Office of Research Administration. For questions about budgeting or negotiating the fee with industry sponsors, please contact Helene Orescan in the Clinical Trials Administration Office.

Sincerely,

James S. Economou
Vice Chancellor for Research